Immunotherapy Safety in Thymic Epithelial Tumors: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System

Immunotherapy Safety in Thymic Epithelial Tumors: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System

Authors of this article:

Ruilian Chen^{1, 2, 3} ;   Hanrui Chen^{1, 3} ;   Lingling Sun^{1, 3} ;   Yang Cao^{1, 3} ;   Lizhu Lin^{1, 3, 4}